• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.

作者信息

Tarantino P, Jin Q, Mittendorf E A, King T A, Curigliano G, Tolaney S M

机构信息

Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA.

Divison of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, USA.

出版信息

Ann Oncol. 2022 Aug;33(8):845-847. doi: 10.1016/j.annonc.2022.04.069. Epub 2022 May 4.

DOI:10.1016/j.annonc.2022.04.069
PMID:35525374
Abstract
摘要

相似文献

1
Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.适合辅助使用阿贝西利的乳腺癌患者的临床和病理特征
Ann Oncol. 2022 Aug;33(8):845-847. doi: 10.1016/j.annonc.2022.04.069. Epub 2022 May 4.
2
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.阿贝西利：治疗乳腺癌的新型 CDK4/6 抑制剂。
Ann Pharmacother. 2019 Feb;53(2):178-185. doi: 10.1177/1060028018795146. Epub 2018 Aug 13.
3
Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.阿贝西利（唯择）——第三种用于乳腺癌的细胞周期蛋白依赖性激酶4/6抑制剂。
Med Lett Drugs Ther. 2017 Nov 6;59(1533):185-186.
4
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.细胞周期蛋白依赖性激酶 4/6 抑制剂在女性晚期或转移性乳腺癌中的应用。
Am J Health Syst Pharm. 2019 Aug 1;76(16):1183-1202. doi: 10.1093/ajhp/zxz121.
5
[Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].[CDK4和6抑制剂阿贝西利在乳腺癌中的研发]
Gan To Kagaku Ryoho. 2021 Dec;48(12):1475-1483.
6
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.nextMONARCH：阿贝西利单药治疗或联合他莫昔芬治疗转移性乳腺癌。
Clin Breast Cancer. 2021 Jun;21(3):181-190.e2. doi: 10.1016/j.clbc.2020.09.011. Epub 2020 Sep 30.
7
Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?转移性 luminal 型乳腺癌中针对同一靶点的不同抑制剂：有何差异？
Future Oncol. 2018 Apr;14(9):891-895. doi: 10.2217/fon-2017-0532. Epub 2018 Mar 12.
8
Abemaciclib: First Global Approval.阿贝西利：全球首次批准。
Drugs. 2017 Dec;77(18):2063-2070. doi: 10.1007/s40265-017-0840-z.
9
Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.辅助阿贝西利联合内分泌治疗： monarchE 队列 1 的疗效结果。
Oncologist. 2023 Jan 18;28(1):e77-e81. doi: 10.1093/oncolo/oyac234.
10
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.一种独特的 CDK4/6 抑制剂：阿贝西利的当前和未来治疗策略。
Pharmacol Res. 2020 Jun;156:104686. doi: 10.1016/j.phrs.2020.104686. Epub 2020 Feb 14.

引用本文的文献

1
Optimizing Adjuvant Care in Early Breast Cancer: Multidisciplinary Strategies and Innovative Models from Canadian Centers.优化早期乳腺癌的辅助治疗：来自加拿大各中心的多学科策略与创新模式
Curr Oncol. 2025 Jul 14;32(7):402. doi: 10.3390/curroncol32070402.
2
Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis.HR+/HER2-早期乳腺癌的真实世界NATALEE和monarchE合格人群特征：美国电子健康记录数据库分析
ESMO Open. 2025 Jun;10(6):105304. doi: 10.1016/j.esmoop.2025.105304. Epub 2025 Jun 13.
3
Clinician's guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer.
临床医生指南：早期乳腺癌患者使用CDK4/6抑制剂的专家见解
Ther Adv Med Oncol. 2025 Mar 20;17:17588359251326710. doi: 10.1177/17588359251326710. eCollection 2025.
4
Exploring the Potential of Adjuvant CDK4/6 Inhibitors in Hormone Receptor-Positive Early Breast Cancer: A Consistent Approach for All.探索辅助性CDK4/6抑制剂在激素受体阳性早期乳腺癌中的潜力：适用于所有人的一致方法。
Cancers (Basel). 2025 Feb 7;17(4):561. doi: 10.3390/cancers17040561.
5
The impact of axillary lymph-node dissection omission on adjuvant abemaciclib eligibility in HR-positive, HER2-negative breast cancer with positive sentinel lymph nodes.在前哨淋巴结阳性的激素受体阳性、人表皮生长因子受体2阴性乳腺癌中，省略腋窝淋巴结清扫对辅助性阿贝西利治疗 eligibility 的影响。（注：这里“eligibility”根据语境可能不太好直接准确翻译，可结合上下文进一步理解其确切含义，比如可能是“适用情况”“符合条件情况”等 ）
Breast Cancer. 2025 May;32(3):543-551. doi: 10.1007/s12282-025-01684-9. Epub 2025 Feb 20.
6
Characteristics, treatment patterns and survival of patients with high-risk early hormone receptor-positive breast cancer in French real-world settings: an exploratory study of the CANTO cohort.法国真实世界中高危早期激素受体阳性乳腺癌患者的特征、治疗模式及生存情况：CANTO队列的探索性研究
ESMO Open. 2024 Dec;9(12):103994. doi: 10.1016/j.esmoop.2024.103994. Epub 2024 Nov 28.
7
Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer.激素受体阳性早期乳腺癌的系统治疗进展。
Curr Treat Options Oncol. 2024 Oct;25(10):1323-1334. doi: 10.1007/s11864-024-01258-5. Epub 2024 Oct 3.
8
Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials.细胞周期蛋白依赖性激酶4/6抑制剂联合内分泌治疗与单纯内分泌治疗用于激素受体阳性、人表皮生长因子受体2阴性早期乳腺癌的疗效比较：III期随机临床试验的荟萃分析
J Pers Med. 2024 Apr 27;14(5):464. doi: 10.3390/jpm14050464.
9
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.GEICAM 辅助研究和 El Álamo IV 登记处高危 HR 阳性和 HER2 阴性早期乳腺癌患者的长期结局。
Breast Cancer Res Treat. 2023 Sep;201(2):151-159. doi: 10.1007/s10549-023-07002-1. Epub 2023 Jun 20.
10
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer.高危早期激素受体阳性、HER2 阴性乳腺癌的系统性治疗新进展。
Curr Treat Options Oncol. 2023 Jun;24(6):594-610. doi: 10.1007/s11864-023-01082-3. Epub 2023 Apr 15.